| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9de5c8f688cbb3c7621171937ea0e760
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a6586ff3dc877c2f3d9d8ae7764341ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be1bf2a6100f98d278cca47eb35222e3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-72 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 |
| filingDate |
2011-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_153e8d1572a41db8993e0702d0704412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85e4581c4ccb70d096f2f30979dd8ad9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4d1ef87434d449b5617c288e2deddc7 |
| publicationDate |
2011-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011275644-A1 |
| titleOfInvention |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| abstract |
The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor that inhibits both IGF-1R and IR kinases. Methods are provided for identifying patients with cancer who are likely to benefit from treatment with an IGF-1R kinase inhibitor that inhibits both IGF-1R and IR kinases. Methods are also provided for identifying patients with cancer who are likely to benefit from treatment with an IGF-1R kinase inhibitor that inhibits both IGF-1R and IR kinases, but who would likely not respond to therapy with an anti-IGF-1R antibody. Methods are also provided for identifying patients with cancer who are more likely to benefit from treatment with anti-IGF-1R antibody. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate these methods are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10041961-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016131665-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011217309-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013106603-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012106556-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013207952-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9255934-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015505055-A |
| priorityDate |
2010-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |